Annandale Capital, LLC Uro Gen Pharma Ltd. Transaction History
Annandale Capital, LLC
- $1.59 Billion
- Q1 2025
A detailed history of Annandale Capital, LLC transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Annandale Capital, LLC holds 75,552 shares of URGN stock, worth $626,326. This represents 0.05% of its overall portfolio holdings.
Number of Shares
75,552
Previous 75,552
-0.0%
Holding current value
$626,326
Previous $805,000
3.85%
% of portfolio
0.05%
Previous 0.13%
Shares
5 transactions
Others Institutions Holding URGN
# of Institutions
142Shares Held
41.6MCall Options Held
91.4KPut Options Held
42.1K-
Ubs Asset Management Americas Inc Chicago, IL4.36MShares$36.1 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY3.83MShares$31.8 Million0.69% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.21MShares$26.6 Million0.74% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$19.1 Million0.17% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$18.2 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $189M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...